Development of metabolic and inflammatory mediator biomarker phenotyping for early diagnosis and triage of pediatric sepsis

Beata Mickiewicz¹, Graham C. Thompson², Jaime Blackwood³, Craig N. Jenne⁴,⁵, Brent W. Winston⁶,⁷, Hans J. Vogel¹, Ari R. Joffe³* and for the Alberta Sepsis Network

Abstract

Introduction: The first steps in goal-directed therapy for sepsis are early diagnosis followed by appropriate triage. These steps are usually left to the physician’s judgment, as there is no accepted biomarker available. We aimed to determine biomarker phenotypes that differentiate children with sepsis who require intensive care from those who do not.

Methods: We conducted a prospective, observational nested cohort study at two pediatric intensive care units (PICUs) and one pediatric emergency department (ED). Children ages 2–17 years presenting to the PICU or ED with sepsis or presenting for procedural sedation to the ED were enrolled. We used the judgment of regional pediatric ED and PICU attending physicians as the standard to determine triage location (PICU or ED). We performed metabolic and inflammatory protein mediator profiling with serum and plasma samples, respectively, collected upon presentation, followed by multivariate statistical analysis.

Results: Ninety-four PICU sepsis, 81 ED sepsis, and 63 ED control patients were included. Metabolomic profiling revealed clear separation of groups, differentiating PICU sepsis from ED sepsis with accuracy of 0.89, area under the receiver operating characteristic curve (AUROC) of 0.96 (standard deviation [SD] 0.01), and predictive ability ($Q^2$) of 0.60. Protein mediator profiling also showed clear separation of the groups, differentiating PICU sepsis from ED sepsis with accuracy of 0.78 and AUROC of 0.88 (SD 0.03). Combining metabolomic and protein mediator profiling improved the model ($Q^2 =0.62$), differentiating PICU sepsis from ED sepsis with accuracy of 0.87 and AUROC of 0.95 (SD 0.01). Separation of PICU sepsis or ED sepsis from ED controls was even more accurate. Prespecified age subgroups (2–5 years old and 6–17 years old) improved model accuracy minimally. Seventeen metabolites or protein mediators accounted for separation of PICU sepsis and ED sepsis with 95% confidence.

Conclusions: In children ages 2–17 years, combining metabolomic and inflammatory protein mediator profiling early after presentation may differentiate children with sepsis requiring care in a PICU from children with or without sepsis safely cared for outside a PICU. This may aid in making triage decisions, particularly in an ED without pediatric expertise. This finding requires validation in an independent cohort.
Introduction

Sepsis is a leading cause of mortality in children worldwide [1]. In children age ≥1 year in the United States, sepsis is the second most common cause of death [2, 3]. The incidence of sepsis in children is increasing. Researchers in one study found an 81 % increase in hospitalizations for severe sepsis between 1995 and 2005 [4–6]. In addition, sepsis may lead to significant physical, neuropsychological, and neurocognitive morbidity in survivors [7–10]. For example, in a recent multicenter study, investigators found that 34 % of survivors of severe sepsis had a decline in their functional status at 28 days, and 18 % were determined to have a “poor” functional outcome (moderate, severe, or vegetative disability) [10].

Early, appropriate antibiotic therapy, fluid resuscitation, and vasoactive support are associated with improved outcomes after sepsis in a highly time-dependent manner [11–13]. The first steps in this therapy are the early diagnosis of sepsis followed by the appropriate stratification of patients (e.g., admission to a hospital ward for observation or to a more intensive monitoring environment in a critical care unit). These first steps are left to the physician’s judgment, as there is currently no accepted, accurate biomarker available to help in making this decision [13–15]. Physicians’ judgment in pediatric emergency departments (EDs) with experienced physicians and in tertiary pediatric intensive care units (PICUs) is likely quite different from that in smaller centers without extensive experience with sepsis in children [16]. The vast majority (>80 %) of children requiring emergency care present to an ED that does not have this specialized pediatric expertise [16, 17]. This problem has led to “great interest in developing diagnostic and stratification biomarkers for sepsis” [18]. A systems biology approach to biomarker phenotyping of the systemic response to sepsis has the potential to provide diagnostic and patient stratification profiles that inform clinical decision-making [19]. Unlike more proximal genomic and transcriptomic analysis, untargeted metabolomics and targeted proteomics reflect the downstream systems-level metabolic processes and pathways at play, defining specific phenotypes and shedding light on underlying pathophysiology [20, 21].

In previous work, our group has found that metabolomic modeling in adults accurately differentiated 39 patients with septic shock patients from 20 intensive care unit (ICU) control patients and that in children, it differentiated 58 PICU patients with septic shock from 39 PICU control patients [22, 23]. In adults, combining metabolomic and protein mediator data more accurately differentiated patients with septic shock from ICU controls [24]. In these studies, our group demonstrated promising metabolic biomarker profiles for diagnosing septic shock in ICU patients. In the present study, we asked different questions:

1. Is there a biomarker-defined phenotype that can differentiate children with sepsis who require intensive care from those who do not?
2. Does combining metabolic profiling with an analysis of protein mediators improve modeling?
3. Are there a limited number of biomarkers that may be used for targeted phenotyping in future studies?

As there is currently no objective gold standard for making this decision in the clinic, we used the judgment of experienced regional pediatric ED and PICU attending physicians as the standard for triage location of care. This standard is the same as that used for telemedicine and pediatric transport systems, where the expertise at the specialized center is relied upon [16].

Methods

Ethical approval

This study was approved by the Health Research Ethics Board of the University of Alberta (Pro00008797) and the Conjoint Health Research Ethics Board of the University of Calgary (Ethics ID 23426).

Patient cohorts

PICU sepsis cohort

The Alberta Sepsis Network (ASN) prospectively enrolled all eligible children up to age 17 years admitted to the only two PICUs in the Province of Alberta, Canada, with a diagnosis of sepsis between April 2010 and October 2013. Sepsis was defined as the systemic inflammatory response syndrome (SIRS) caused by a suspected or proven bacterial or fungal infection [25], with antibiotics ordered and an arterial and/or central venous line in place. Patients not expected to survive ≥24 h, refusing intubation or vasoactive infusions (i.e., palliative care), or already having had severe sepsis for ≥48 h (defined as sepsis with cardiovascular dysfunction, acute respiratory distress syndrome, or two other organ dysfunctions) [25] were excluded. Demographic, infection and severity-of-illness variables (including pediatric logistic organ dysfunction [PELOD] and Pediatric Risk of Mortality [PRISM III] scores) were recorded prospectively [26, 27]. Blood was drawn as soon as possible on the day the patient met the eligibility criteria, using deferred consent. If consent was subsequently refused, the blood was not used and the patient was not enrolled. Patients were divided into the predefined 2–5-year-old and 6–17-year-old age groups on the basis of suspected pathophysiology, as done by others [23, 25], with microbiologically confirmed sepsis (positive culture from a normally sterile site, including blood, cerebrospinal fluid, peritoneal fluid, or tissue) or pneumonia without microbiological confirmation (SIRS with chest infiltrate suggestive of pneumonia). We did not
consider sputum or endotracheal aspirates as sterile site cultures or require them as confirmatory of pneumonia, and it is not current practice to perform bronchoalveolar lavage in patients with suspected pneumonia. The site of infection was defined as that diagnosed by the attending medical team.

**ED sepsis cohort**
The ASN prospectively enrolled all children age ≤17 years admitted to one pediatric ED in Alberta with a diagnosis of sepsis. *Sepsis* was defined as SIRS caused by a suspected or proven bacterial or fungal infection [25], with antibiotics and blood culture ordered. Patients who were admitted to the PICU from the ED were included in the PICU sepsis cohort and not in the ED sepsis cohort. Basic demographic information was recorded, and blood was drawn as soon as possible on the day the patient met the eligibility criteria after informed consent was obtained. The site of infection was defined as that diagnosed by the attending medical team.

**ED control cohort**
In the same pediatric ED, all previously healthy children age ≤17 years admitted for a procedure and without an infection (i.e., no history of fever within 2 weeks and no clinical evidence of infection) were prospectively enrolled. These children had traumatic lacerations, fractures and/or dislocations, or foreign body removal requiring intravenous sedation and/or analgesia. Blood was drawn after consent was obtained, and basic demographic information was recorded.

**Sample collection and preparation**
Samples were obtained via an existing arterial or central venous catheter (PICU sepsis cohort) or an intravenous tube insertion or blood culture draw (ED cohorts). Sample processing was performed as described in Additional file 1.

**Proton nuclear magnetic resonance spectroscopy and metabolite concentration profiling**
Proton nuclear magnetic resonance (1H-NMR) spectra were acquired on a Bruker AVANCE-II 600 MHz spectrometer (Bruker BioSpin, Milton, ON, Canada). All spectra were randomly ordered for untargeted profiling to avoid progressive bias. Untargeted profiling involves identification of different compounds by their characteristic spectral signature using information that is stored in an external metabolite reference database [28–30]. Detailed methods are described in Additional file 1.

**Protein mediator profiling**
Quantification of targeted protein mediators (cytokines, chemokines, and acute-phase proteins involved in inflammation) was done using validated Luminex bead-based multiplexing assays according to manufacturer’s instructions (Luminex, Austin, TX, USA). Detailed methods are described in Additional file 1.

**Statistical modeling**
Multivariate statistical analysis was performed using the SIMCA-P+ software (v12.0.1; Umetrics, Umeå, Sweden) [19, 31–35]. All metabolites or protein mediators with >50 % missing values were excluded from analysis. Data preprocessing (median fold change normalization, logarithmic transformation, centering, and unit variance scaling) was first conducted separately for the metabolic and protein mediator datasets and then for the combined dataset [33]. An unsupervised principal component analysis (PCA) was performed to obtain an overview of the multivariate dataset and to identify and exclude outliers that could seriously disturb the supervised models [31]. Outliers are defined as those samples that are situated outside the 95 % confidence interval of the Hotelling’s T2 distribution (elliptical or spherical area in the score scatterplot) [31]. Then, supervised partial least squares discriminant analysis (PLS-DA) and orthogonal PLS-DA (OPLS-DA) models were developed to determine the best class discrimination (PICU sepsis, ED sepsis, and ED control) based on the preprocessed original data [31–35]. The OPLS-DA method was applied to models including only two classes. The OPLS-DA models for the combined datasets were based on potentially relevant metabolites and protein mediator data selected using the variable importance to projection (VIP), and only those variables with VIP >1 were chosen [31]. In supervised analysis, R2Y (the percentage of variation explained by the model) and Q2 (the predictive ability of the model) metrics were calculated using a sevenfold cross-validation method [31, 36]. Additionally, the OPLS-DA models were validated by calculating coefficient of variation-analysis of variance p values and the receiver operating characteristic curve (ROC) (Metz ROC Software; University of Chicago, Chicago, IL USA) [37, 38]. The sensitivity, specificity, and accuracy were determined on the basis of sample class prediction during sevenfold cross-validation (Y-predcv) using SIMCA-P+ software. To describe specific biopatterns for 2–17-year-old children using combined NMR and protein mediator data, the OPLS-DA regression coefficients were calculated and metabolites and/or protein mediators with significant changes in concentration (p <0.05) were considered as the most important variables [31].

**Results**
**Description of the cohorts**
The demographics, sites of infection, and severity-of-illness measures for each age and category cohort are given in Table 1. Children meeting ASN eligibility were
Table 1 Description of the three cohorts of patients

| Descriptive variable                        | PICU sepsis cohort | ED sepsis cohort | ED control cohort |
|--------------------------------------------|--------------------|------------------|------------------|
| Age (mo)                                   | 39 (13.8)          | 138 (45)         | 45 (13)          |
| Males                                      | 18 (50 %)          | 34 (59 %)        | 16 (64 %)        |
| Weight (kg)                                | 14.4 (4.5)         | 40.2 (20.5)      | 17.2 (3.0)       |
| Underlying comorbidity                     |                    |                  | N/A              |
| Neuromuscular                               | 10 (28 %)          | 3 (7 %)          | N/A              |
| Cardiac                                    | 9 (25 %)           | 0                | N/A              |
| Respiratory                                 | 5 (14 %)           | 2 (5 %)          | N/A              |
| PRISM III score                            | 11 (9); 10 [2–18]  | 8 (7); 7 [3–11]  | N/A              |
| PELOD score                                | 16.7 (9.4); 13 [11–22] | 11.5 (7.6); 12 [10–13] | N/A |
| WBC count (10⁹/Litre)                      | 12.9 (10.3)        | 13.6 (8.7)       | N/A              |
| Platelet count (10⁹/Litre)                 | 185 (124)          | 191 (127)        | N/A              |
| Creatinine (µmol/L)                        | 53 (48)            | 60 (39)          | N/A              |
| Lactate (mmol/L)                           | 2.1 (1.9)          | 2.4 (2.5)        | N/A              |
| Lowest SBP (mmHg)                          | 77 (13)            | 92 (17)          | 106 (11)         |
| Lowest MAP (mmHg)                          | 54 (8)             | 63 (13)          | N/A              |
| pH                                         | 7.3 (0.1)          | 7.3 (0.1)        | N/A              |
| Sepsis developed after first PICU day      | 6 (17 %)           | 4 (7 %)          | N/A              |
| Site of infection                          | N/A                | N/A              | N/A              |
| Pneumonia without microbiological confirmation | 21 (58 %)          | 28 (48 %)        | N/A              |
| Microbiologically confirmed (culture positive) | 15 (42 %)         | 12 (28 %)        | N/A              |
| Clinically diagnosed                       | 0 (0 %)            | 8 (19 %)         | N/A              |
| Mechanical ventilation on first day        | 27 (75 %)          | 38 (67 %)        | N/A              |
| Inotrope/vasopressor infusion on first day | 20 (56 %)          | 34 (57 %)        | N/A              |
| Duration of mechanical ventilation after enrollment (days) | 10 [5–13]       | 6 [3–8]          | N/A              |

Mickiewicz et al. Critical Care (2015) 19:320
| PICU length of stay after enrollment (days) | <2 days: 2 (6 %) | <2 days: 4 (7 %) | Hospital stay | Hospital stay | N/A | N/A |
|-------------------------------------------|-----------------|-----------------|---------------|---------------|-----|-----|
| RRT                                       | 4 (11 %)        | 2 (4 %)         | 0             | 0             | N/A | N/A |
| ECLS therapy                              | 6 (17 %)        | 4 (7 %)         | 0             | 0             | N/A | N/A |
| PICU mortality                             | 1 (3 %)         | 1 (2 %)         | 0             | 0             | 0   | 0   |

Abbreviations: ECLS extracorporeal life support, MAP mean arterial pressure, N/A not applicable, PELOD pediatric logistic organ dysfunction, PICU pediatric intensive care unit, PRISM Pediatric Risk of Mortality, RRT renal replacement therapy, SBP systolic blood pressure; WBC white blood cells.

Results are given as n (%) or mean (SD) or median [IQR].

a Sites of infection included meningitis (n = 2), bacteremia (n = 7), empyema (n = 4), mediastinitis (n = 1), and peritonitis (n = 3)

b Sites of infection included meningitis (n = 9), bacteremia (n = 12), empyema (n = 3), peritonitis (n = 7), and fasciitis (n = 1)

c Sites of infection included microbiologically confirmed meningitis (n = 3), bacteremia (n = 1), peritonitis (n = 2), urinary tract infection (n = 4), and Streptococcus pyogenes throat culture (n = 2) and clinically diagnosed otitis media with draining ear or mastoiditis (n = 3), cellulitis (n = 2), cervical adenitis (n = 1), and other (n = 2)

d Sites of infection included microbiologically confirmed bacteremia (n = 3), peritonitis (n = 7), urinary tract infection (n = 4), otitis media with S. pyogenes throat infection (n = 5), clinically diagnosed otitis media with mastoiditis (n = 2), osteomyelitis (n = 1), pelvic abscess (n = 1), toxic shock syndrome (n = 1), and other (3)
prospectively entered into the PICU-ASN database after deferred consent was obtained (refusal rate of 22 %). Of 205 patients in the PICU-ASN database, those under 24 months of age \((n =63)\), with missing data \((n =3)\), or without clear bacterial sepsis (unknown, viral or other causes of SIRS) were excluded from this PICU sepsis nested cohort. The PICU sepsis cohort patients had PELOD and PRISM III severity-of-illness scores comparable to other PICU sepsis trial patients \([39, 40]\). Most PICU patients were ventilated (for about 1 week) and received supportive vasoactive infusions on the first day of sepsis. A significant number required renal replacement therapy and extracorporeal life support during their PICU stay. The average PICU length of stay after sepsis was about 1 week. The ED sepsis cohorts showed comparable demographics, except for having fewer comorbidities and better values for platelet count and systolic blood pressure. The ED control cohorts had proportionately more male subjects. Only 3 (3 %) of 94 of the PICU sepsis cohort were admitted to the PICU from the ward; these 3 patients had blood for analysis drawn in the ED, and none were outliers in the models.

2–17-year-old children

Ninety-four PICU sepsis, 81 ED sepsis, and 63 ED control patients were included. A total of 58 metabolites and 48 protein mediators were recognized and quantified for each patient (Additional file 1: Table E1). Totals of 1.12 % and 2.01 % missing values were observed in the NMR and protein mediator datasets, and these were randomly distributed.

Profiling

Metabolomic profiling

Three principal components (PCs) were calculated via cross-validation to build the PCA model, with good data grouping, explaining the following percentages of variation: PC1 17.7 %, PC2 11.7 %, and PC3 7.4 % (Fig. 1a and Additional file 2: Figure E7a). There were nine outliers comprising 6 (6 %) in the PICU sepsis cohort and 3 (4 %) in the ED sepsis cohort. These outliers were excluded from subsequent analyses. A supervised PLS-DA showed that the three different cohorts were well clustered, with specific metabolic profiles for each. The model showed excellent goodness of fit (cumulative \(R^2_Y =0.56\)) and goodness of prediction (cumulative \(Q^2 =0.47\)) (Fig. 2a). The OPLS-DA method was applied to compare metabolic variance in patient groups consisting of only two classes. The score scatterplots for each statistical analysis show clear separation of groups, with high values for the \(R^2_Y\) and \(Q^2\) parameters (Fig. 3a and Table 2). The predictive accuracy statistics for differentiating PICU sepsis from ED sepsis (Table 2) show accuracy of 0.89 and area under the ROC (AUROC) of 0.96 (standard deviation [SD] 0.01).

Protein mediator profiling

PCA revealed three PCs explaining the following percentages of variation: PC1 19.4 %, PC2 14.6 %, and PC3 7.6 % (Fig. 1b and Additional file 2: Figure E7b). A total of 20 outliers comprising 13 (14 %) in the PICU sepsis cohort, 4 (5 %) in the ED sepsis cohort, and 3 (5 %) in the ED control cohort were excluded from further analyses. The PLS-DA model shows that the three different cohorts are reasonably well clustered, with an \(R^2_Y\) cumulative score of 0.54 and a \(Q^2\) cumulative score of 0.47 (Fig. 2b). The score scatterplots for each OPLS-DA statistical analysis show clear separation of groups, with high values for the \(R^2_Y\) and \(Q^2\) parameters (Fig. 3b and Table 2). The predictive accuracy statistics for differentiating PICU sepsis from ED sepsis (Table 2) showed accuracy of 0.78 and AUROC of 0.88 (SD 0.03), which were not as high as the values for NMR metabolomics.

Combined results

When PCA was performed, a three-PC model explained the following percentages of variation: PC1 21.5 %, PC2 8.7 %, and PC3 6.5 % (Fig. 1c and Additional file 2: Figure E7c). There were eight outliers comprising seven (7 %) in the PICU sepsis cohort and one (1 %) in the ED sepsis cohort. These outliers were excluded from subsequent analyses. A supervised PLS-DA shows that the three different cohorts are well clustered, with excellent model descriptive values: cumulative \(R^2_Y =0.63\) and cumulative \(Q^2 =0.56\) (Fig. 2c). The score scatterplots for each OPLS-DA statistical analysis show clear separation of the groups, with high values for the \(R^2_Y\) and \(Q^2\) parameters (Fig. 3c and Table 2). The predictive accuracy statistics for differentiating PICU sepsis from ED sepsis (Table 2) show accuracy of 0.87 and AUROC 0.95 (SD 0.01). This model had very similar accuracy statistics compared with NMR alone; however, the sensitivity was higher (0.90 vs 0.86), the specificity was lower (0.85 vs 0.91), and goodness of prediction was higher (\(Q^2 =0.62\) vs 0.60).

Models without outliers excluded

To confirm that the outliers detected in the PCA models (and subsequently excluded) did not bias the results of the supervised analyses, we recalculated the PLS-DA and OPLS-DA models including all outliers. This had only minor influence on the discriminative and predictive ability of the models (Additional file 1: Table E2). For example, for the combined dataset model differentiating PICU sepsis from ED sepsis, \(R^2_Y =0.67\) and \(Q^2 =0.63\) compared with the model with outliers excluded where \(R^2_Y =0.69\) and \(Q^2 =0.62\).

Age subgroups

Full details of the results for the separate metabolomic and protein mediator analyses and the combined analyses
Most meaningful metabolites and protein mediators
Using the combined data, a total of 14 metabolites and 3 protein mediators defined the most significant differences responsible for the separation between PICU sepsis and ED sepsis cohorts in the OPLS-DA model (Fig. 4).

Discussion
The main findings of this nested cohort comparison of three groups of patients ages 2–17 years with or without sepsis include the following. First, our metabolomic analysis using $^1$H-NMR spectroscopy clearly distinguished patients with sepsis requiring care in a PICU ($n = 94$) from those with sepsis in the ED ($n = 81$) and those without sepsis in the ED (controls, $n = 63$) never requiring care in a PICU, with few outliers excluded from the
model (6% of the PICU sepsis cohort). Second, protein mediator profiling also distinguished between these groups; however, there were more outliers that had to be excluded from these analyses, limiting the accuracy of this method alone. Third, combining metabolomic and protein mediator data produced relatively few outliers (7% of the PICU sepsis cohort), AUROC of 0.95 (SD 0.01), and the strongest model ($Q^2$ =0.62), being more informative than either dataset alone. Fourth, the prespecified age subgroups resulted in only marginally more accurate models, but at the price of smaller patient numbers, and more outliers were excluded from model development. Fifth, a small group of 17 metabolites and protein mediators accounted for the separation of PICU sepsis and ED sepsis cohorts with 95% confidence. Taken together, our data suggest that development of a laboratory test using these findings to help make diagnostic and triage decisions in children with sepsis is feasible.
These results are important for several reasons. First, they demonstrate proof of concept for using biomarker phenotyping in a clinical environment, generating information on patient biology that can guide clinicians’ diagnosis and triage decisions [19]. Second, the potential of this biomarker phenotyping has been demonstrated in a disease where decisions are time-sensitive [11–13]. In sepsis, poor decisions can mean the difference between survival and death and between survival with or without significant functional and/or neurocognitive sequelae [7–13]. For example, in meningococcemia, the symptoms in the first 4–6 h are non-specific, and many children are initially misdiagnosed by their physicians [41]. Third, these results were obtained in children, and regionalization of clinical experience in pediatric EDs and PICUs leaves most hospitals where children present without the specialized expertise to make timely diagnostic and triage decisions [16, 17]. Biomarker phenotyping accurately tracked the clinical decisions made by the specialized pediatric physicians, differentiating a PICU cohort that had high need for ventilation and vasoactive infusions and a prolonged PICU length of stay from an ED cohort that did not require the specialized and costly care of a PICU. Fourth, by using this discovery and systems biology–based approach, we identified a limited number of metabolites and protein mediators of interest that may realistically lead to development of a point-of-care decision aid and inform future research into the mechanisms of severe sepsis in children.

Whether the 17 metabolites and mediators of interest cause or are the result of manifestations of sepsis cannot be determined on the basis of the observational design of our study. Nevertheless, overall, they suggest broad changes in metabolic and inflammatory processes induced by severe sepsis, identified together as a specific biopattern to inform patient triage and possible pathophysiological mechanisms (see Additional file 1). For example, the metabolite changes suggest PICU sepsis–associated enhanced...
Table 2  Accuracy results of orthogonal partial least squares discriminant analysis models

| Age group | Data   | Outliers in PICU sepsis cohort, n (%) | R²Y | Q² | p Value | Sensitivity; specificity | PPV; NPV | Accuracy | AUROC (SD) |
|-----------|--------|--------------------------------------|-----|----|---------|-------------------------|---------|----------|------------|
| 2–17 yr   | Metabolites | 6 (6 %)                              | 0.69 | 0.60 | 3.9×10⁻¹¹ | 0.86; 0.91 | 0.92; 0.86 | 0.89 | 0.96 (0.01) |
|           | Mediators     | 13 (14 %)                            | 0.58 | 0.42 | 4.9×10⁻¹⁷ | 0.79; 0.77 | 0.78; 0.78 | 0.78 | 0.88 (0.03) |
|           | Combined      | 7 (7 %)                              | 0.69 | 0.62 | 5.9×10⁻³³ | 0.90; 0.85 | 0.87; 0.88 | 0.87 | 0.95 (0.01) |
| 2–5 yr    | Metabolites   | 3 (8 %)                              | 0.68 | 0.50 | 4.4×10⁻¹⁰ | 0.76; 0.95 | 0.93; 0.83 | 0.87 | 0.95 (0.03) |
|           | Mediators     | 6 (17 %)                             | 0.67 | 0.45 | 1.8×10⁻⁷ | 0.73; 0.83 | 0.76; 0.81 | 0.79 | 0.91 (0.04) |
|           | Combined      | 5 (14 %)                             | 0.78 | 0.65 | 8.0×10⁻¹⁵ | 0.87; 0.93 | 0.90; 0.91 | 0.90 | 0.98 (0.02) |
| 6–17 yr   | Metabolites   | 6 (10 %)                             | 0.79 | 0.68 | 2.0×10⁻²⁰ | 0.94; 0.92 | 0.94; 0.92 | 0.93 | 0.97 (0.01) |
|           | Mediators     | 9 (16 %)                             | 0.67 | 0.45 | 4.5×10⁻¹⁰ | 0.86; 0.76 | 0.82; 0.80 | 0.81 | 0.91 (0.03) |
|           | Combined      | 5 (9 %)                              | 0.82 | 0.76 | 2.7×10⁻²⁵ | 0.94; 0.92 | 0.94; 0.92 | 0.93 | 0.99 (0.01) |

Abbreviations: AUROC area under the receiver operating characteristic curve, NPV negative predictive value, PICU pediatric intensive care unit, PPV positive predictive value, SD standard deviation

fatty acid breakdown, ketoacidosis, and dysfunction in amino acid metabolism [30]; hepatic glycogen catabolism [42]; and disruption in glycerophospholipid and sulfur metabolism [30]. The protein mediator changes suggest altered leukocyte recruitment and function [43–45]. A representative metabolic pathway network identified the most impaired biological pathways in PICU sepsis: taurine and hypotaurine metabolism; glycine, serine, and threonine metabolism; aminoacyl–transfer RNA biosynthesis; pyruvate metabolism; and, in 6–17-year-olds, arginine and proline metabolism [46]. This is similar to the most perturbed pathways in a previous PICU septic shock (vs PICU control) cohort [23].

This study has some limitations. It was performed at two centers, and the ED cohorts were from one center, possibly limiting the generalizability of the results. The number of patients included in each cohort was modest. The exact timing of the onset of sepsis in patients is unclear, as some present at different times in the course of the systemic response. In addition, the time from presentation until blood was drawn was likely different in the PICU sepsis and ED sepsis cohorts. We cannot be sure if different models would be obtained if stricter criteria for time course were applied. The PICU and ED sepsis cohorts were broadly separated by age groups a priori, but not strictly matched for age, sex, and clinical severity, and the definition of sepsis was more stringent in the PICU cohort. The ED control group was meant to reflect children with acute stress known not to be due to infection; thus, that group included children with predominantly fractures and lacerations. We did not determine whether the model could differentiate PICU sepsis and ED sepsis from other non-sepsis diagnoses that may require intensive care. Nevertheless, these patients were recruited from the only two PICUs serving the Province of Alberta and much of Northern Canada, with a catchment population >4 million. The biomarker phenotyping was applied in the real-world setting of patients presenting to the hospital with sepsis, regardless of the exact time of onset of their disease. Finally, the number of patients included is the largest sample for biomarker phenotyping in children of which we are aware [18, 19, 22, 23, 47].

We did not compare our biomarker phenotyping with existing Pediatric Early Warning Scores (PEWSs) used in the ED. We do not believe that this is a major limitation, for several reasons. First, most of these scores include, in addition to vital signs, subjective descriptions of the level of consciousness, capillary refill, work of breathing, and worry about clinical status [48]. The goal of our model is to allow decisions that do not rely on this subjective expertise. Second, evaluations of the existing PEWSs have concluded that they are not accurate enough to replace clinical judgment, having inadequate discriminant ability for predicting PICU admission [48–51]. A related limitation is that we did not determine whether PICU sepsis patients initially presented with obvious fluid-refractory or vasoactive-dependent sepsis making a biomarker unnecessary. We retrospectively determined timing of interventions in ASN patients admitted to one PICU and found that, in patients ventilated on day 1 of sepsis, the times from initial presentation to 20 ml/kg volume bolus or vasoactive infusions were, on average, >3 h and >8 h, respectively. This suggests that few patients were declared to have fluid-refractory or vasoactive-dependent septic shock in the first hours after presentation to the ED.

A prospective validation of our findings in an independent multicenter cohort using clear definitions of sepsis upon presentation to an ED is needed. Although there is need for some caution [52, 53], we believe that developing a point-of-care test targeted at detecting the metabolites and protein mediators of interest identified here holds great promise, as recently found for gene expression mosaics [54]. This may involve enzyme-linked immunosorbent assay or novel, rapid liquid chromatography-mass spectrometry techniques [55, 56].
Conclusions

In children ages 2–17 years, combining metabolomic and inflammatory protein mediator profiling early after presentation can differentiate children with sepsis requiring care in a PICU from children with or without sepsis who can be safely cared for outside a PICU. By using this discovery and systems biology–based approach, we identified a limited number of metabolites and protein mediators of interest that may realistically lead to development of a point-of-care decision aid. This may aid triage decisions, particularly in EDs without pediatric expertise. This finding requires validation in an independent cohort.

Key messages

- In children ages 2–17 years, combining metabolomic and inflammatory protein mediator profiling on serum and plasma early after presentation can differentiate children with sepsis requiring care in a PICU from children with or without sepsis who can be safely cared for outside a PICU.
- By using this discovery and systems biology–based approach, we identified a limited number of metabolites and protein mediators of interest that may realistically lead to development of a point-of-care decision aid.
Additional files

Additional file 1: Supplemental descriptions of methods, statistical modeling, results of subgroups, discussion of the importance of the metabolites and protein mediators of interest (biomarkers) identified, and supplemental references. This file also includes two tables. Table E1. The metabolites (non-targeted: 1H NMR spectroscopy and metabolite concentration profiling) and protein mediators (targeted bead-based multiplex assay) detected and quantified. Table E2. Comparison of statistical measures calculated for the supervised OPLS-DA models without excluding outliers from the results presented in the main text of the article. (PDF 307 kb)

Additional file 2: Results of the metabolomic and protein mediator biomarker phenotyping in the two age subgroups. This file contains six figures depicting the results for the age subgroups and a seventh figure showing the loading plots that demonstrate which metabolites and/or inflammatory protein mediators contribute most to each component in the PCA models for the age 2–17-year-old cohort. (PDF 4020 kb)

Abbreviations
ASN: Alberta Sepsis Network; AUROC: area under the receiver operating characteristic curve; ECLS: extracorporeal life support; ED: emergency department; 1H-NMR: proton nuclear magnetic resonance; ICU: intensive care unit; MAP: mean arterial pressure; NPV: negative predictive value; OPLS-DA: orthogonal partial least squares discriminant analysis; PCA: principal component analysis; PELOD: pediatric logistic organ dysfunction score; PICU: pediatric intensive care unit; PPV: positive predictive value; PRISM: Pediatric Risk of Mortality; ROC: receiver operating characteristic curve; RRT: renal replacement therapy; SBP: systolic blood pressure; SD: standard deviation; SIRS: systemic inflammatory response syndrome; VIP: variable importance to projection; WBC: white blood cells.

Competing interests
This study was supported by the Alberta Innovates-Health Solutions team grant to the Alberta Sepsis Network. BM, BWW, and HJV hold patent US 20140205591 A1 (Metabolite Biomarkers for Diagnosis and Prognosis of Pediatric Septic Shock). None of the other authors has any competing interests or other financial disclosures to make. The funding agency had no role in the design and conduct of the study; the collection, management, analysis, or interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.

Authors’ contributions
ARJ, BM, GT, JB, CJN, BWW, and HJV contributed to study conception and design, acquisition and interpretation of data, and revision of the manuscript critically for intellectual content. ARJ drafted the manuscript. BM revised the statistics section of the manuscript and drafted part of the Discussion section. CJN revised the Methods section and drafted part of the Discussion section. BM and HJV performed the statistical analysis. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work. ARJ had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Acknowledgments
We thank the following for their help with this project: Josee Wong and the Critical Care Epidemiologic and Biologic Tissue Resource for specimen handling, Derrice Knight for her organizational skills as the project manager for the Alberta Sepsis Network, Mandy Tse and the Snyder Translational Laboratory in Critical Care Medicine for protein mediator analysis, and the pediatric research coordinators who managed the consent process and data collection and entry.

Author details
1 Bio-NMR Center, Department of Biological Sciences, University of Calgary, Calgary, AB, Canada. 2Division of Emergency Medicine, Department of Pediatrics, University of Calgary, Calgary, AB, Canada. 3Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Alberta, 4-546 Edmonton Clinic Health Academy; 11405 87 Avenue, Edmonton, AB T6G 1C9, Canada. 4Calvin, Phoebe and Joan Snyder Institute for Chronic Diseases, University of Calgary, Calgary, AB, Canada. 5Department of Critical Care Medicine, University of Calgary, Calgary, AB, Canada. 6Department of Medicine, University of Calgary, Calgary, AB, Canada. 7Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, AB, Canada.

Received: 7 May 2015 Accepted: 12 August 2015
Published online: 09 September 2015

References
1. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379:2151–61.
2. Watson RS, Carcillo JA. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med. 2005;6(Suppl):S3–5.
3. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Liddicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167:695–701.
4. Hartman ME, Linde-Zwirble W, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis. Pediatr Crit Care Med. 2012;13:686–93.
5. Dombrovsky YV, Martin AA, Sanderam J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007;35:1244–50.
6. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54.
7. Als LC, Nadel S, Cooper M, Pierce CM, Sahakiian BJ, Garralda ME. Neuropsychologic function three to six months following admission to the PICU with meningococcritis, sepsis, and other disorders: a prospective study of school-aged children. Crit Care Med. 2013;41:1094–103.
8. Bronner MB, Knehneter H, Sol JJ. An exploratory study on quality of life and psychological and cognitive function in pediatric survivors of septic shock. Pediatr Crit Care Med. 2009;10:636–42.
9. Conlon MP, Breathnach C, O’Hare BP, Mannion DW, Lyons BJ. Health related quality of life after prolonged pediatric intensive care unit stay. Pediatr Crit Care Med. 2009;10:41–4.
10. Farris RW, Weiss NS, Zimmerman J. Functional outcomes in pediatric severe sepsis: further analysis of the researching severe sepsis and organ dysfunction in children. A global perspective trial. Pediatr Crit Care Med. 2013;14:835–42.
11. Weiss SL, Fitzgerald JC, Balasumith, A, Alpner E, Lavelle J, Chilutti M, et al. Delayed antimicrobial therapy increases mortality and organ dysfunction duration in pediatric sepsis. Crit Care Med. 2014;42:2409–17.
12. Beck V, Chateau D, Bryson GL, Pospis A, Zanotti S, Parrillo JE, et al. Timing of vasopressor initiation and mortality in septic shock: a cohort study. Crit Care. 2014;18(R):R7.
13. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. Crit Care Med. 2013;41:680–637.
14. Fischer JE. Physicians’ ability to diagnose sepsis in newborns and critically ill children. Pediatr Crit Care Med. 2005;6(Suppl):S120–S.
15. Wacker C, Prkno A, Brunkenhorst FM, Schlattmann P, Pocacottinin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13:426–35.
16. Committee on the Future of Emergency Care in the United States Health System, Board on Health Care Services, Institute of Medicine. Emergency care for children: growing pains. Washington, DC: The National Academies Press; 2007.
17. Canadian Institute for Health Information (CIHI). Emergency departments and children in Ontario. Ottawa, ON, Canada: CIHI; April 2008 https://secure.cihi.ca/free_products/aib_apr24_08_en.pdf. Accessed 21 August 2015.
18. Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med. 2011;12:615–73.
19. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC. Metabolic phenotyping in clinical and surgical environments. Nature. 2012;491:384–91.
20. Kehnophot M, Nin N, Bauer M. Metabolism, metabolome, and metabolomics in intensive care: is it time to move beyond monitoring of glucose and lactate? Am J Resp Crit Care Med. 2013;187:906–7.
21. Bancoi MM, Donnelly SJ, Mickiewicz B, Weljie A, Vogel HJ, Winston BW. Metabolomics in critical care medicine: a new approach to biomarker discovery. Clin Invest Med. 2014;37:E363–76.

22. Mickiewicz B, Duggan GE, Winston BW, Doig C, Kubes P, Vogel HJ, et al. Metabolic profiling of serum samples by 1H nuclear magnetic resonance spectroscopy as a potential diagnostic approach for septic shock. Crit Care Med. 2014;42:1143–9.

23. Mickiewicz B, Vogel HJ, Wong HR, Winston BW. Metabolomics as a novel approach for early diagnosis of pediatric septic shock and its mortality. Am J Respir Crit Care Med. 2013;187:967–76.

24. Mickiewicz B, Tam P, Jenne CN, Leger C, Wong J, Winston BW, et al. Integration of metabolic and inflammatory mediator profiles as a potential prognostic approach for septic shock in the intensive care unit. Crit Care. 2015;19:1111.

25. Goldstein B, Ginor B, Randolph A, International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2–8.

26. Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet. 2003;362:192–7. A published erratum appears in. Lancet. 2006;367:902.

27. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 2014;42:743–52.

28. Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and 13C NMR spectroscopy of human blood plasma. Anal Chem. 1995;67:793–811.

29. Weljie AM, Newton J, Mercier P, Carlson E, Slupsky CM. Targeted profiling: Multi- and megavariate data analysis. Part I: basic principles and applications. Umeå, Sweden: Umetrics; 2006. p. 425.

30. Eriksson L, Johansson E, Kettaneh-Wold N, Trygg J, Wikström C, Wold S. Metabolic profiling of serum samples by 1H nuclear magnetic resonance spectroscopy. Anal Chem. 2001;73:861

31. van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ. Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC Genomics. 2006;7:142.

32. Trygg J, Holm E, Lundstedt T. Chemometrics in metabolomics. J Proteome Res. 2007;6:469–79.

33. Madson R, Lundstedt T, Trygg J. Chemometrics in metabolomics: a review in human disease diagnosis. Anal Chim Acta. 2010;659:23–33.

34. Picard RR, Cook DR. Cross-validation of regression models. J Am Stat Assoc. 1984;79:575–83.

35. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett. 2006;27:861–74.

36. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–77.

37. Chooong K, Bohn D, Fraser DD, Gaboury I, Hutchison JS, Joffe AR, et al. Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial. Am J Respir Crit Care Med. 2009;180:652–9.

38. Menon K, Ward RE, Lawson ML, Gaboury I, Hutchison JS, Hebert PC. A prospective multicenter study of adrenal function in critically ill adolescents. Am J Respir Crit Care Med. 2014;189:246–51.

39. Thompson MJ, Ninis N, Perera R, Mayon-White R, Phillips C, Bailey L, et al. Soluble tumor necrosis factor related apoptosis inducing ligand level as a predictor of severity of sepsis and the risk of mortality in septic patients. PLoS One. 2013;8:e82204.

40. Xia J, Mandel R, Sinelnickij I, Broadhurst D, Wishart DS. MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 2012;40:W127–33.

41. Fanos V, Caboni G, Grontani M, Gazzolo D, Noto A, et al. Urinary H-NMR and GC-MS metabolomics predicts early and late onset neonatal sepsis. Early Hum Dev. 2014;90 Suppl 1:578–83.

42. Seiger N, Maconochie I, Oostenbrink R, Mo ll H A. Validity of different pediatric early warning scores in the emergency department. Pediatrics. 2013;132:e841–50.

43. Gold DL, Mihalov UK, Cohen DM. Evaluating the Pediatric Early Warning Score (PEWS) system for admitted patients in the pediatric emergency department. Acad Emerg Med. 2014;21:1249–56.

44. Beslin K, Marx J, Hoffman H, McBeth R, Pavuluri P. Pediatric Early Warning Score at time of emergency department disposition is associated with level of care. Pediatr Emer Care. 2014;30:97–103.

45. Bradman K, Borland M, Pascoe E. Predicting patient disposition in a paediatric emergency department. J Paediatr Child Health. 2014;50:E39–44.

46. Kentis A, Lin YY, Kurek C, Calicchio M, Wang YY, Mongiatti F, et al. Discovery and validation of urine markers of acute pediatric appendicitis using high-accuracy mass spectrometry. Ann Emerg Med. 2009;53:62–70.

47. Kentis A, Ahmed S, Kurek C, Brennan E, Bradford G, Steen H, et al. Detection and diagnostic value of urine leucine-rich α-2-glycoprotein in children with suspected acute appendicitis. Ann Emerg Med. 2012;60:78–83.e1.

48. Wong HR, Cuvajnovich NZ, Anas N, Allen GL, Thomas NJ, Bigham MT, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015;191:305–15.

49. Tudds AL, Beselink GAJ, Schafstall RBM. Trends in miniaturized total analysis systems for point-of-care testing in clinical chemistry. Lab Chip. 2001;1:83–95.

50. Bell C, George C, Kicman AT, Traynor A. Development of a rapid LC-MS/MS method for direct urinalysis of designer drugs. Drug Test Anal. 2011;3:496–504.